{
  "symbol": "VCEL",
  "company_name": "Vericel Corporation",
  "ir_website": "https://www.vcel.com/investor-relations/contact/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "http://investors.vcel.com/press-releases",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Press Releases \n\n#  Press Releases \n\nCategory: CorporateFinancial\n\nYear: - Any -2024202320222021202020192018201720162015201420132012201120102009200820072006200520042003\n\n- Any -\n\n[Date](?mobile=1&items_per_page=10&order=field_nir_news_date&sort=asc \"sort by Date\") | [Title and Summary](?mobile=1&items_per_page=10&order=field_nir_news_title&sort=asc \"sort by Title and Summary\") | Additional Formats  \n---|---|---  \n[Toggle Summary](#)November 7, 2024 |  [Vericel Reports Third Quarter 2024 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2024-financial-results) Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov.  |  [View HTML](/news-releases/news-release-details/vericel-reports-third-quarter-2024-financial-results) [PDF Version](/node/22216/pdf)  \n[Toggle Summary](#)October 24, 2024 |  [Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024](/news-releases/news-release-details/vericel-report-third-quarter-2024-financial-results-november-7) CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024.  |  [View HTML](/news-releases/news-release-details/vericel-report-third-quarter-2024-financial-results-november-7) [PDF Version](/node/22206/pdf)  \n[Toggle Summary](#)August 29, 2024 |  [Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024](/news-releases/news-release-details/vericel-present-morgan-stanley-global-healthcare-conference-0) CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- &nbsp;Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan  |  [View HTML](/news-releases/news-release-details/vericel-present-morgan-stanley-global-healthcare-conference-0) [PDF Version](/node/22081/pdf)  \n[Toggle Summary](#)August 26, 2024 |  [Vericel Announces FDA Approval and Commercial Availability of MACI Arthro](/news-releases/news-release-details/vericel-announces-fda-approval-and-commercial-availability-maci) First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACIâ€™s $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports  |  [View HTML](/news-releases/news-release-details/vericel-announces-fda-approval-and-commercial-availability-maci) [PDF Version](/node/22061/pdf)  \n[Toggle Summary](#)August 15, 2024 |  [Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns](/news-releases/news-release-details/vericel-announces-fda-approval-nexobrid-treatment-pediatric) Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S.  |  [View HTML](/news-releases/news-release-details/vericel-announces-fda-approval-nexobrid-treatment-pediatric) [PDF Version](/node/22026/pdf)  \n[Toggle Summary](#)August 7, 2024 |  [Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024](/news-releases/news-release-details/vericel-present-canaccord-genuity-growth-conference-wednesday) CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m.  |  [View HTML](/news-releases/news-release-details/vericel-present-canaccord-genuity-growth-conference-wednesday) [PDF Version](/node/21996/pdf)  \n[Toggle Summary](#)August 1, 2024 |  [Vericel Reports Second Quarter 2024 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2024-financial-results) Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profitability Guidance Raised to 71% Gross Margin and 21% Adjusted EBITDA Margin Conference Call Today  |  [View HTML](/news-releases/news-release-details/vericel-reports-second-quarter-2024-financial-results) [PDF Version](/node/21976/pdf)  \n[Toggle Summary](#)July 22, 2024 |  [Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer](/news-releases/news-release-details/vericel-announces-appointment-karen-mahoney-chief-human) CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who  |  [View HTML](/news-releases/news-release-details/vericel-announces-appointment-karen-mahoney-chief-human) [PDF Version](/node/21956/pdf)  \n[Toggle Summary](#)July 18, 2024 |  [Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024](/news-releases/news-release-details/vericel-report-second-quarter-2024-financial-results-august-1) CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024.  |  [View HTML](/news-releases/news-release-details/vericel-report-second-quarter-2024-financial-results-august-1) [PDF Version](/node/21926/pdf)  \n[Toggle Summary](#)June 11, 2024 |  [Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024](/news-releases/news-release-details/vericel-present-truist-securities-medtech-conference-tuesday) CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist  |  [View HTML](/news-releases/news-release-details/vericel-present-truist-securities-medtech-conference-tuesday) [PDF Version](/node/21836/pdf)  \n  \nDay High: Day Low: Volume: \n\non \n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Events & Presentations",
          "url": "http://investors.vcel.com/events-presentations",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Events & Presentations \n\n#  Events & Presentations \n\nUpcoming Events \n\nMore events are coming soon. \n\nPresentations \n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n\nArchived Events \n\n[Listen to Webcast](https://edge.media-server.com/mmc/p/as3nx9j3)\n\nNov 7, 2024 at 8:30 AM EST \n\n[Vericel Corporation Third Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2024-earnings-call)\n\nSupporting Materials\n\n[Vericel Q3 2024 Earnings Presentation](/static-files/2310fdcb-c402-4bd3-b4d9-192b0f78b41e \"Vericel Q3 2024 Earnings Call Presentation FINAL.pdf\") 334.5 KB\n\n[Listen to Webcast](https://event.webcasts.com/starthere.jsp?ei=1685713&tp_key=406a6bbb76&tp_special=8)\n\nSep 6, 2024 at 1:05 PM EDT \n\n[Morgan Stanley 22nd Annual Global Healthcare Conference](/events/event-details/morgan-stanley-22nd-annual-global-healthcare-conference)\n\n[Listen to Webcast](https://wsw.com/webcast/canaccord98/register.aspx?conf=canaccord98&page=vcel&url=https%3A//wsw.com/webcast/canaccord98/vcel/2454870)\n\nAug 14, 2024 at 3:00 PM EDT \n\n[Canaccord Genuity 44th Annual Growth Conference](/events/event-details/canaccord-genuity-44th-annual-growth-conference)\n\n[Listen to Webcast](https://edge.media-server.com/mmc/p/oksm8gyb)\n\nAug 1, 2024 at 8:30 AM EDT \n\n[Vericel Corporation Second Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2024-earnings-call)\n\nSupporting Materials\n\n[Vericel Q2 2024 Earnings Presentation](/static-files/47a43395-9c11-418f-b130-6f21558946a3 \"Vericel Q2 2024 Earnings Call Presentation FINAL.pdf\") 371.5 KB\n\n[Listen to Webcast](https://wsw.com/webcast/truist5/register.aspx?conf=truist5&page=vcel&url=https%3A//wsw.com/webcast/truist5/vcel/2064000)\n\nJun 18, 2024 at 2:30 PM EDT \n\n[Truist Securities MedTech Conference](/events/event-details/truist-securities-medtech-conference)\n\n[Listen to Webcast](https://wsw.com/webcast/leerink34/vcel/2209770)\n\nMay 29, 2024 at 9:40 AM EDT \n\n[Leerink Partners Healthcare Crossroads Conference 2024](/events/event-details/leerink-partners-healthcare-crossroads-conference-2024)\n\nDay High: Day Low: Volume: \n\non \n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "Quarterly Results",
      "links": [
        {
          "title": "Quarterly Results",
          "url": "http://investors.vcel.com/financial-information/quarterly-results",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Quarterly Results \n\n#  Quarterly Results \n\n[Show all](#)\n\nYear: All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Submit\n\n## 2024\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2024-earnings-call)\n\n  * [Vericel Reports Third Quarter 2024 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2024-financial-results)\n\n  * [Vericel Q3 2024 Earnings Presentation](/static-files/2310fdcb-c402-4bd3-b4d9-192b0f78b41e \"Vericel Q3 2024 Earnings Call Presentation FINAL.pdf\") 334.5 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-24-046015)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2024-earnings-call)\n\n  * [Vericel Reports Second Quarter 2024 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2024-financial-results)\n\n  * [Vericel Q2 2024 Earnings Presentation](/static-files/47a43395-9c11-418f-b130-6f21558946a3 \"Vericel Q2 2024 Earnings Call Presentation FINAL.pdf\") 371.5 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-24-033905)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2024-earnings-call)\n\n  * [Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance](/news-releases/news-release-details/vericel-reports-first-quarter-2024-financial-results-and-raises)\n\n  * [Vericel Q1 2024 Earnings Presentation](/static-files/1289798c-3326-416a-baa4-913e56b1a2bb \"Vericel Q1 2024 Earnings Call Presentation FINAL.pdf\") 377.8 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-24-021399)\n\n\n\n\n## 2023\n\nQ4 Earnings\n\n  * [Vericel Corporation Fourth Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-fourth-quarter-2023-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2023-financial)\n\n  * [Vericel Q4 2023 Earnings Presentation](/static-files/32f5c309-bcc3-4dfa-91ff-e7bc8b0fe248 \"Vericel Q4 2023 Earnings Call Presentation FINAL.pdf\") 426.4 KB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-24-007824)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2023-earnings-call)\n\n  * [Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-third-quarter-2023-financial-results-and-raises)\n\n  * [Vericel Q3 2023 Earnings Presentation](/static-files/53e54db8-82a5-4fed-adf7-c96ce39b722f \"Vericel Q3 2023 Earnings Call Presentation 11-8-23 FINAL.pdf\") 576 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-23-037583)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2023-earnings-call)\n\n  * [Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-second-quarter-2023-financial-results-and-raises)\n\n  * [Vericel Q2 2023 Earnings Presentation](/static-files/32bbb9de-68e5-4596-af69-187b5c7890d5 \"Vericel Q2 2023 Earnings Call Presentation 8-2-23 FINAL.pdf\") 775.1 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-23-026596)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2023-earnings-call)\n\n  * [Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-first-quarter-2023-financial-results-and-raises)\n\n  * [Vericel Q1 2023 Earnings Presentation](/static-files/415f02cb-2253-4e5c-9e7d-85b2271db709 \"Vericel Q1 2023 Earnings Call Presentation 5-10-23 FINAL.pdf\") 518.4 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-23-017039)\n\n\n\n\n## 2022\n\nQ4 Earnings\n\n  * [Vericel Corporation Fourth Quarter 2022 Earnings Call](/events/event-details/vericel-corporation-fourth-quarter-2022-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2022-financial)\n\n  * [Vericel Q4 2022 Earnings Presentation](/static-files/768d7615-9f4b-4ae2-8a11-a232a739993c \"Vericel Q4 2022 Earnings Call Presentation 2-23-23 FINAL.pdf\") 1.2 MB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-23-004714)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2022 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2022-earnings-call)\n\n  * [Vericel Reports Third Quarter 2022 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2022-financial-results)\n\n  * [Vericel Q3 2022 Earnings Presentation](/static-files/e8d8b7c6-f0fb-4991-8ceb-0f201fee37b1 \"Vericel Q3 2022 Earnings Call Presentation 11-9-22 FINAL.pdf\") 943 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-22-029082)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2022 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2022-earnings-call)\n\n  * [Vericel Reports Second Quarter 2022 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2022-financial-results)\n\n  * [Vericel Q2 2022 Earnings Presentation](/static-files/be6e36a3-34cb-4e80-a712-9e8567911026 \"Vericel Q2 2022 Earnings Call Presentation 8-3-22 FINAL.pdf\") 980.9 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-22-020355)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2022 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2022-earnings-call)\n\n  * [Vericel Reports First Quarter 2022 Financial Results](/news-releases/news-release-details/vericel-reports-first-quarter-2022-financial-results)\n\n  * [Vericel Q1 2022 Earnings Presentation](/static-files/38284448-1199-401e-9702-39b738a4ebbb \"Vericel Q1 2022 Earnings Call Presentation 5-4-22_FINAL.pdf\") 1.4 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-22-012151)\n\n\n\n\n## 2021\n\nQ4 Earnings\n\n  * [Vericel Corporation Fourth Quarter 2021 Earnings Call](/events/event-details/vericel-corporation-fourth-quarter-2021-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2021-financial)\n\n  * [Vericel Q4 2021 Earnings Presentation](/static-files/3b6e2cbd-28e6-456b-a94c-ed74cacb420a \"Vericel Q4 2021 Earnings Call Presentation 2-24-22 FINAL.pdf\") 1.1 MB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-22-003661)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2021 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2021-earnings-call)\n\n  * [Vericel Reports Third Quarter 2021 Financial Results ](/news-releases/news-release-details/vericel-reports-third-quarter-2021-financial-results)\n\n  * [Vericel Q3 2021 Earnings Presentation](/static-files/3d40f894-9261-4701-b8a2-3282f6579a1d \"Vericel Q3 2021 Earnings Call Presentation 11-9-21 FINAL.pdf\") 836.9 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-21-022419)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2021 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2021-earnings-call)\n\n  * [Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance](/news-releases/news-release-details/vericel-reports-second-quarter-2021-financial-results-and-raises)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-21-015540)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2021 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2021-earnings-call)\n\n  * [Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance](/news-releases/news-release-details/vericel-reports-first-quarter-2021-financial-results-and-raises)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-21-008983)\n\n\n\n\n## 2020\n\nQ4 Earnings\n\n  * [Vericel Corporation Fourth Quarter 2020 Earnings Call](/events/event-details/vericel-corporation-fourth-quarter-2020-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2020-financial)\n\n  * [Vericel Q4 2020 Earnings Presentation](/static-files/11f309bb-aeef-44d8-902c-55c9f84f4ffb \"Vericel Q4 2020 Earnings Call Presentation 2-24-21 FINAL_Adj 3-2-2021.pdf\") 818.9 KB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-21-003081)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2020 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2020-earnings-call)\n\n  * [Vericel Reports Record Third Quarter Revenues and Net Income](/news-releases/news-release-details/vericel-reports-record-third-quarter-revenues-and-net-income)\n\n  * [Vericel Q3 2020 Earnings Presentation](/static-files/d005c515-4c18-4b1b-885e-1ae6c11a4133 \"Vericel Q3 2020 Earnings Call Presentation.pdf\") 1.2 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-20-015697)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2020 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2020-earnings-call)\n\n  * [Vericel Reports Second Quarter 2020 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2020-financial-results)\n\n  * [Vericel Q2 2020 Earnings Presentation](/static-files/4d8a57ae-5289-4647-bb85-38e5ab3d5d34 \"Vericel Q2 2020 Earnings Call Presentation.pdf\") 1.2 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-20-011753)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2020 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2020-earnings-call)\n\n  * [Vericel Reports First Quarter 2020 Financial Results](/news-releases/news-release-details/vericel-reports-first-quarter-2020-financial-results)\n\n  * [Vericel Q1 2020 Earnings Presentation](/static-files/35b96ca5-0f99-4e97-a847-912acc8d815c \"Vericel Q1 2020 Earnings Call Presentation.pdf\") 1.3 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-20-007473)\n\n\n\n\n## 2019\n\nQ4 Earnings\n\n  * [Vericel Corporation Fourth Quarter 2019 Earnings Call](/events/event-details/vericel-corporation-fourth-quarter-2019-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2019-financial)\n\n  * [Vericel Q4 2019 Earnings Presentation](/static-files/02e8a9b8-3239-4b71-8ce9-43a3f7a0990c \"Vericel Q4 2019 Earnings Call Presentation.pdf\") 1.4 MB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-20-002229)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2019 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2019-earnings-call)\n\n  * [Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow](/news-releases/news-release-details/vericel-reports-record-third-quarter-revenues-net-income-and)\n\n  * [Vericel Q3 2019 Earnings Presentation](/static-files/14bb544c-1ead-405d-b7ea-e4713bafb773 \"Vericel Q3 2019 Earnings Presentation.pdf\") 1.4 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-19-013312)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2019 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2019-earnings-call)\n\n  * [Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance](/news-releases/news-release-details/vericel-reports-second-quarter-2019-financial-results-and-raises)\n\n  * [Vericel Q2 2019 Earnings Presentation](/static-files/361a8381-a965-44ca-a70e-76ddec012177 \"Vericel Q2 2019 Earnings Presentation.pdf\") 1.4 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-19-010077)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2019 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2019-earnings-call)\n\n  * [Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance](/news-releases/news-release-details/vericel-reports-first-quarter-2019-financial-results-and-raises)\n\n  * [Vericel Q1 2019 Earnings Presentation](/static-files/0cc5712c-a196-43be-a711-84d6c314e7e0 \"Vericel â€“ Q1 2019 Earnings Presentation.pdf\") 1.4 MB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-19-006102)\n\n\n\n\n## 2018\n\nQ4 Earnings\n\n  * [Vericel Corporation Fourh Quarter 2018 Earnings Call ](/events/event-details/vericel-corporation-fourh-quarter-2018-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2018-financial)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-19-002007)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Corporation Third Quarter 2018 Earnings Call ](/events/event-details/vericel-corporation-third-quarter-2018-earnings-call)\n\n  * [Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance](/news-releases/news-release-details/vericel-reports-record-third-quarter-revenues-225-million-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-18-013767)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Corporation Second Quarter 2018 Earnings Call ](/events/event-details/vericel-corporation-second-quarter-2018-earnings-call)\n\n  * [Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance](/news-releases/news-release-details/vericel-reports-record-second-quarter-revenues-190-million-and-0)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-18-010558)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2018 Earnings Call ](/events/event-details/vericel-corporation-first-quarter-2018-earnings-call)\n\n  * [Vericel Reports First Quarter 2018 Financial Results](/news-releases/news-release-details/vericel-reports-first-quarter-2018-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-18-006239)\n\n\n\n\n## 2017\n\nQ4 Earnings\n\n  * [Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-year-end-2017-financial)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-18-002753)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Reports Third-Quarter 2017 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2017-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-17-011022)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Reports Second-Quarter 2017 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2017-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-17-008431)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Corporation First Quarter 2017 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2017-earnings-call)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-17-005367)\n\n\n\n\n## 2016\n\nQ4 Earnings\n\n  * [Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-year-end-2016-financial)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-17-002492)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Reports Third-Quarter 2016 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2016-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-16-020936)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Reports Second-Quarter 2016 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2016-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-16-018710)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Reports First-Quarter 2016 Financial Results](/news-releases/news-release-details/vericel-reports-first-quarter-2016-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-16-016063)\n\n\n\n\n## 2015\n\nQ4 Earnings\n\n  * [Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-year-end-2015-financial)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-16-012668)\n\n\n\n\nQ3 Earnings\n\n  * [Vericel Reports Third-Quarter 2015 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2015-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-15-008745)\n\n\n\n\nQ2 Earnings\n\n  * [Vericel Reports Second-Quarter 2015 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2015-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-15-006531)\n\n\n\n\nQ1 Earnings\n\n  * [Vericel Reports First-Quarter 2015 Financial Results](/news-releases/news-release-details/vericel-reports-first-quarter-2015-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-15-004203)\n\n\n\n\n## 2014\n\nQ4 Earnings\n\n  * [Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-year-end-2014-financial)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001104659-15-022712)\n\n\n\n\nQ3 Earnings\n\n  * [Aastrom Biosciences Reports Third-Quarter 2014 Financial Results](/news-releases/news-release-details/aastrom-biosciences-reports-third-quarter-2014-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-14-080198)\n\n\n\n\nQ2 Earnings\n\n  * [Aastrom Biosciences Reports Second Quarter 2014 Financial Results](/news-releases/news-release-details/aastrom-biosciences-reports-second-quarter-2014-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-14-060912)\n\n\n\n\nQ1 Earnings\n\n  * [Aastrom Biosciences Reports First-Quarter 2014 Financial Results](/news-releases/news-release-details/aastrom-biosciences-reports-first-quarter-2014-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-14-039355)\n\n\n\n\n###  NASDAQ: VCEL \n\n$57.32 | -1.42 (-2.42%)  \n---|---  \n  \nDay High: $59.42 Day Low: $56.90 Volume: 109,704 \n\n12:44 PM EST on Dec 3, 2024\n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "Stock Quote & Analyst Coverage",
      "links": [
        {
          "title": "Stock Quote & Analyst Coverage",
          "url": "http://investors.vcel.com/investor-relations#stock-quote",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\nDay High: Day Low: Volume: \n\non \n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n\n### \n\nESG Report\n\n[![cover image esg report](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/06/30/11-43-40/cover-esg-report.png?itok=JUCeRIw1) ](/static-files/b7fb0a8a-0772-45a2-9977-954fbb54998e)\n\n[ESG Report](/static-files/b7fb0a8a-0772-45a2-9977-954fbb54998e \"Vericel ESG Report 2021 - FINAL.pdf\") 3.6 MB\n\n#  Investor Relations \n\n## Press Releases\n\nNovember 7, 2024 \n\n###  Vericel Reports Third Quarter 2024 Financial Results \n\n[Read More](/news-releases/news-release-details/vericel-reports-third-quarter-2024-financial-results)\n\n[PDF Version](/node/22216/pdf)\n\nOctober 24, 2024 \n\n###  Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 \n\n[Read More](/news-releases/news-release-details/vericel-report-third-quarter-2024-financial-results-november-7)\n\n[PDF Version](/node/22206/pdf)\n\nAugust 29, 2024 \n\n###  Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 \n\n[Read More](/news-releases/news-release-details/vericel-present-morgan-stanley-global-healthcare-conference-0)\n\n[PDF Version](/node/22081/pdf)\n\n[See All](/press-releases)\n\n## Events and Presentations\n\nUpcoming Events \n\nMore events are coming soon. \n\nPresentations \n\n[Company Presentation ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[See All](/events-presentations)\n\n## Quarterly Results\n\n[Show all](#)\n\n## 2024\n\nQ3\n\n  * [Vericel Corporation Third Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2024-earnings-call)\n\n  * [Vericel Reports Third Quarter 2024 Financial Results](/news-releases/news-release-details/vericel-reports-third-quarter-2024-financial-results)\n\n  * [Vericel Q3 2024 Earnings Presentation](/static-files/2310fdcb-c402-4bd3-b4d9-192b0f78b41e \"Vericel Q3 2024 Earnings Call Presentation FINAL.pdf\") 334.5 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-24-046015)\n\n\n\n\nQ2\n\n  * [Vericel Corporation Second Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2024-earnings-call)\n\n  * [Vericel Reports Second Quarter 2024 Financial Results](/news-releases/news-release-details/vericel-reports-second-quarter-2024-financial-results)\n\n  * [Vericel Q2 2024 Earnings Presentation](/static-files/47a43395-9c11-418f-b130-6f21558946a3 \"Vericel Q2 2024 Earnings Call Presentation FINAL.pdf\") 371.5 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-24-033905)\n\n\n\n\nQ1\n\n  * [Vericel Corporation First Quarter 2024 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2024-earnings-call)\n\n  * [Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance](/news-releases/news-release-details/vericel-reports-first-quarter-2024-financial-results-and-raises)\n\n  * [Vericel Q1 2024 Earnings Presentation](/static-files/1289798c-3326-416a-baa4-913e56b1a2bb \"Vericel Q1 2024 Earnings Call Presentation FINAL.pdf\") 377.8 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-24-021399)\n\n\n\n\n## 2023\n\nQ4\n\n  * [Vericel Corporation Fourth Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-fourth-quarter-2023-earnings-call)\n\n  * [Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance](/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2023-financial)\n\n  * [Vericel Q4 2023 Earnings Presentation](/static-files/32f5c309-bcc3-4dfa-91ff-e7bc8b0fe248 \"Vericel Q4 2023 Earnings Call Presentation FINAL.pdf\") 426.4 KB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001628280-24-007824)\n\n\n\n\nQ3\n\n  * [Vericel Corporation Third Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-third-quarter-2023-earnings-call)\n\n  * [Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-third-quarter-2023-financial-results-and-raises)\n\n  * [Vericel Q3 2023 Earnings Presentation](/static-files/53e54db8-82a5-4fed-adf7-c96ce39b722f \"Vericel Q3 2023 Earnings Call Presentation 11-8-23 FINAL.pdf\") 576 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-23-037583)\n\n\n\n\nQ2\n\n  * [Vericel Corporation Second Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-second-quarter-2023-earnings-call)\n\n  * [Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-second-quarter-2023-financial-results-and-raises)\n\n  * [Vericel Q2 2023 Earnings Presentation](/static-files/32bbb9de-68e5-4596-af69-187b5c7890d5 \"Vericel Q2 2023 Earnings Call Presentation 8-2-23 FINAL.pdf\") 775.1 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-23-026596)\n\n\n\n\nQ1\n\n  * [Vericel Corporation First Quarter 2023 Earnings Call](/events/event-details/vericel-corporation-first-quarter-2023-earnings-call)\n\n  * [Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance](/news-releases/news-release-details/vericel-reports-first-quarter-2023-financial-results-and-raises)\n\n  * [Vericel Q1 2023 Earnings Presentation](/static-files/415f02cb-2253-4e5c-9e7d-85b2271db709 \"Vericel Q1 2023 Earnings Call Presentation 5-10-23 FINAL.pdf\") 518.4 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001628280-23-017039)\n\n\n\n\n[See All](/financial-information/quarterly-results)\n\n## Stock Quote & Analyst Coverage\n\n### **Stock Quote ()**\n\nChange  \n---  \nVolume  \nToday's Open  \nPrevious Close  \nToday's High  \nToday's Low  \n52 Week High  \n52 Week Low  \n  \n[See Stock Chart](#)\n\n##### VCEL Stock Chart\n\nÃ—\n\n[Sign up for email alerts](/email-alerts)\n\nVericel Corporation is covered by the following analysts. \n\n**Ryan Zimmerman**\n\nBTIG\n\n**Caitlin Cronin**\n\nCanaccord Genuity \n\n**Swayampakula Ramakanth**\n\nH.C. Wainwright & Co.\n\n**Jeff Cohen**\n\nLadenburg Thalmann\n\n**Mike Kratky**\n\nLeerink\n\n**Mason Carrico**\n\nStephens\n\n**Joshua Jennings, MD**\n\nTD Cowen\n\n**Richard Newitter**\n\nTruist\n\nVericel Corporation is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\n## Annual Reports & Proxy Statements\n\nAnnual Reports \n\n[2023 Annual Report ](/static-files/77d218c3-c2b0-46e4-b14b-e561265193aa)\n\n[2022 Annual Report](/static-files/93a4bf02-5ad5-415a-9d78-787a743a3097)\n\n[2021 Annual Report](/static-files/e66502be-2f89-4e28-bdda-fa52a87074d4)\n\nProxy Statements \n\n[2024 Proxy Statement](/static-files/2350fd5b-e78d-462f-b049-c58015c16f8f)\n\n[2023 Proxy Statement](/static-files/7f3f119f-9b74-41cf-a554-e7c5efa7b43e)\n\n[2022 Proxy Statement](/static-files/b12ca6f1-5574-4911-8fbd-22c5fa9a8a8b)\n\n[See All](/annual-reports-and-proxies)\n\nTo view Vericel's SEC Filings, [click here](/sec-filings)\n\nTo view Vericel's Corporate Governance Documents, [click here](/corporate-governance)\n\n## Vericel Board of Directors\n\n[Click here](https://vcel.com/investor-relations/board-of-directors/index.html) to learn more about the Vericel Board of Directors.\n\n[Go](https://vcel.com/investor-relations/board-of-directors/index.html)\n\n## Frequently Asked Questions\n\nHave questions? [Click here](/investor-faqs) to visit our Investor FAQ page.\n\n[Go](/investor-faqs)\n\n## Contact Vericel\n\nNeed additional information? [Click here](https://vcel.com/contact/) to contact Vericel or [Click here](/email-alerts) to sign up for Vericelâ€™s investor email list.\n\n[Go](/email-alerts)\n"
        }
      ]
    },
    {
      "section_name": "Annual Reports & Proxy Statements",
      "links": [
        {
          "title": "Annual Reports & Proxy Statements",
          "url": "http://investors.vcel.com/annual-reports-and-proxies",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Annual Reports and Proxies \n\n#  Annual Reports and Proxies \n\nAnnual Reports \n\n[2023 Annual Report ](/static-files/77d218c3-c2b0-46e4-b14b-e561265193aa \"VCEL002_Vericel_2023-Annual-Report_Web.pdf\") 1.5 MB\n\n[2022 Annual Report](/static-files/93a4bf02-5ad5-415a-9d78-787a743a3097 \"412912\\(1\\)_3_Vericel 2022 AR_PR_R1.pdf\") 1.6 MB\n\n[2021 Annual Report](/static-files/e66502be-2f89-4e28-bdda-fa52a87074d4 \"2021 10-K.pdf\") 1.5 MB\n\nProxy Statements \n\n[2024 Proxy Statement](/static-files/2350fd5b-e78d-462f-b049-c58015c16f8f \"Vericel Corporation 2024 Proxy Statement \\(final\\).pdf\") 4 MB\n\n[2023 Proxy Statement](/static-files/7f3f119f-9b74-41cf-a554-e7c5efa7b43e \"412911\\(1\\)_16_Vericel 2023 NPS_WR.pdf\") 5.5 MB\n\n[2022 Proxy Statement](/static-files/b12ca6f1-5574-4911-8fbd-22c5fa9a8a8b \"Vericel Corporation 2022 Proxy Statement.pdf\") 3.7 MB\n\n[Click here to sign-up for E-Delivery of Proxy Materials](https://enroll.icsdelivery.com/vcel)\n\nDay High: Day Low: Volume: \n\non \n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "ESG Report",
      "links": [
        {
          "title": "ESG Report",
          "url": "https://investors.vcel.com/static-files/b7fb0a8a-0772-45a2-9977-954fbb54998e",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "http://investors.vcel.com/sec-filings",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  SEC Filings \n\n#  SEC Filings \n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | View  \n---|---|---|---  \nDec 02, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-008337) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22291/html) [0001959173-24-008337.pdf](/static-files/e60ad0f1-2fb5-4206-8837-0c53baff2960)  \nNov 25, 2024 | [4](/sec-filings/sec-filing/4/0001140361-24-047758) | Statement of changes in beneficial ownership of securities | [View HTML](/node/22286/html) [0001140361-24-047758.pdf](/static-files/c474178c-f188-455a-b0fa-c73acbf5a717) [0001140361-24-047758.xls](/static-files/24e0aca5-fde2-4fe9-8d35-44c1460ff759)  \nNov 22, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-008103) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22281/html) [0001959173-24-008103.pdf](/static-files/93c790a6-1e14-46b1-b561-49d600041411) [0001959173-24-008103.xls](/static-files/5443d570-b9f5-451d-91ae-b34d21250475)  \nNov 15, 2024 | [4](/sec-filings/sec-filing/4/0001140361-24-047070) | Statement of changes in beneficial ownership of securities | [View HTML](/node/22271/html) [0001140361-24-047070.pdf](/static-files/a78f45e9-3737-4053-9ff4-10c637904626) [0001140361-24-047070.xls](/static-files/af17072d-1fa7-471a-a6ed-90386aa0b8a8)  \nNov 15, 2024 | [4](/sec-filings/sec-filing/4/0001140361-24-047069) | Statement of changes in beneficial ownership of securities | [View HTML](/node/22276/html) [0001140361-24-047069.pdf](/static-files/e016b189-eadc-4ab1-93fe-e6949189e443) [0001140361-24-047069.xls](/static-files/2d5f716c-7f1e-4484-bdab-89b097ebf073)  \nNov 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000902664-24-006489) | An amendment to the SC 13G filing | [View HTML](/node/22256/html) [0000902664-24-006489.pdf](/static-files/9743dce7-1e30-4b9b-8115-81bffad13265) [0000902664-24-006489.xls](/static-files/f35ada6a-b634-46af-935b-eb7beba480ee)  \nNov 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001398344-24-020824) | An amendment to the SC 13G filing | [View HTML](/node/22261/html) [0001398344-24-020824.pdf](/static-files/43b08f22-68ff-47af-88f7-07928850f761) [0001398344-24-020824.xls](/static-files/098cf1cc-f31d-4a99-91f6-7bccdafa8702)  \nNov 14, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007850) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22266/html) [0001959173-24-007850.pdf](/static-files/c9df3b3f-22e3-4c12-a915-aa297698f1d5) [0001959173-24-007850.xls](/static-files/dea86fbe-01fa-4ada-abaf-a39ebd423ba9)  \nNov 13, 2024 | [4](/sec-filings/sec-filing/4/0001140361-24-046456) | Statement of changes in beneficial ownership of securities | [View HTML](/node/22241/html) [0001140361-24-046456.pdf](/static-files/9543af4a-aedb-4ad0-af31-ec059ef9f8b0) [0001140361-24-046456.xls](/static-files/817520fc-c3ad-4461-a3a9-360a82fed0a9)  \nNov 13, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007813) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22246/html) [0001959173-24-007813.pdf](/static-files/d708cf2d-99e3-476d-8b61-dba004af89f3)  \nNov 13, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007817) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22251/html) [0001959173-24-007817.pdf](/static-files/5c8affa3-5145-4fee-be60-482ce772635d) [0001959173-24-007817.xls](/static-files/8f585d9f-181f-4158-a6b5-762800a56bf1)  \nNov 12, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007643) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22231/html) [0001959173-24-007643.pdf](/static-files/dc808141-621c-4a5d-999b-700c93ef3899)  \nNov 12, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007722) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [View HTML](/node/22236/html) [0001959173-24-007722.pdf](/static-files/1db51081-2b9a-4232-b6c3-652e5bfbc7c3)  \nNov 07, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-045997) | Report of unscheduled material events or corporate event | [View HTML](/node/22221/html) [0001628280-24-045997.pdf](/static-files/432b0fb6-53d0-46fd-ab4d-ad37ca4bc8d7) [0001628280-24-045997.xls](/static-files/33e07f9a-295d-4343-aa3d-a68660e86685)  \nNov 07, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001628280-24-046015) | Quarterly report which provides a continuing view of a company's financial position | [View HTML](/node/22226/html) [0001628280-24-046015.pdf](/static-files/0756a6cc-1b7c-40e8-8ffa-ef219fd1d74d) [0001628280-24-046015.xls](/static-files/903022cd-ecae-4dde-8396-c3dad33c01ea)  \n  \nData provided by [Kaleidoscope](https://www.kscope.io).\n\n###  NASDAQ: VCEL \n\n$57.32 | -1.42 (-2.42%)  \n---|---  \n  \nDay High: $59.42 Day Low: $56.90 Volume: 109,704 \n\n12:44 PM EST on Dec 3, 2024\n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "http://investors.vcel.com/corporate-governance",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Corporate Governance \n\n#  Corporate Governance \n\nThe Board of Directors of Vericel Corporation (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\n[Corporate Governance Guidelines](/static-files/a9510a51-dd1d-461c-918d-03f730350164 \"Vericel Corporate Governance Guidelines \\(7.28.21\\).pdf\") 472.2 KB\n\n[Code of Business Conduct and Ethics](/static-files/8d930778-453f-42b1-966a-63dc99a26bfc \"Vericel Code of Business Conduct and Ethics \\(revised Oct 2023\\).pdf\") 454.8 KB\n\n[Code of Ethics for Senior Financial Officers](/static-files/998f3d33-389c-447e-9d98-ae6e6d0edfaa \"ASTM_WebDoc_1257.pdf\") 11.6 KB\n\n[ Special Trading Procedures (for Insiders)](/static-files/76addb53-1b3a-44d9-ae82-5e449b5b1b13 \"Special Trading Procedures for Insiders \\(revised May 2023\\).pdf\") 715.3 KB\n\n[Shareholder Communications with Directors Policy](/static-files/60f40cb7-45c0-45a8-bbc7-986142c4a08c \"Shareholder Communications with Directors Policy \\(2020\\).pdf\") 192.1 KB\n\n[Insider Trading Policy](/static-files/5dbf7e2f-b93d-4980-b7f3-abf53ff314bb \"Insider Trading Policy \\(Revised May 2023\\).pdf\") 744.9 KB\n\n[Director Nominations Policy](/static-files/78744c82-f583-4d17-b9c6-0772e285fd59 \"Director Nominations Policy \\(revised Feb 11 2020\\).pdf\") 272.9 KB\n\n[Board Member Attendance at Annual Meetings Policy](/static-files/adae0f9f-150a-43f4-85a1-2ae1ef6b7f21 \"Board Member Attendance at Annual Meetings Policy \\(2020\\).pdf\") 185.6 KB\n\n[Charter of the Audit Committee of the Board of Directors](/static-files/cff5be31-37bc-446a-950d-5772b6724022 \"Charter of the Audit Committee of the Board of Directors \\(2020\\).pdf\") 363.9 KB\n\n[Charter of the Compensation Committee of the Board of Directors](/static-files/00d56608-60be-4490-a215-873119e84f80 \"Charter of the Compensation Committee February 2024.pdf\") 292 KB\n\n[Charter of the Governance and Nominating Committee of the Board of Directors](/static-files/c51fd86f-a981-484e-903f-4fa7d2ba6b34 \"Charter of the Governance and Nominating Committee -- Vericel Corporation \\(revised February 2022\\).pdf\") 170.3 KB\n\n###  NASDAQ: VCEL \n\n$57.32 | -1.42 (-2.42%)  \n---|---  \n  \nDay High: $59.42 Day Low: $56.90 Volume: 109,704 \n\n12:44 PM EST on Dec 3, 2024\n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "FAQ",
      "links": [
        {
          "title": "FAQ",
          "url": "http://investors.vcel.com/investor-faqs",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Investor FAQs \n\n#  Investor FAQs \n\n##  Where is Vericel Corporation's stock traded? \n\nVericel Corporation Stock is traded on the Nasdaq Capital Market. The symbol is **VCEL.**\n\n##  Where are Vericel Corporation's headquarters located? \n\n**Headquarters:** Vericel Corporation 64 Sidney Street Cambridge, MA 02139 Phone: (617) 252-7999 Fax: (617) 252-7555 [Click here](http://vcel.com/about-vericel/contact/?ref=investors) for full contact information. \n\n##  Can I buy Vericel Corporation's stock directly from the Company? \n\nVericel Corporation does not currently offer a direct stock purchase program. \n\n##  Does Vericel Corporation pay a dividend? \n\nVericel Corporation does not currently pay dividends. \n\n##  Who is Vericel Corporation's transfer agent? \n\n**Registrar and Transfer Agent** Continental Stock Transfer & Trust Company 17 Battery Place, 8th Floor New York, NY 10004 Phone: (212) 509-4000 \n\n##  What is Vericel Corporation's fiscal year? \n\nVericel Corporation's fiscal year begins on January 1 and ends on December 31. \n\n##  Who is Vericel Corporation's Auditor? \n\n**Auditors** PricewaterhouseCoopers LLP 225 South Sixth Street, Suite 1400 Minneapolis, MN 55402 Phone: (612) 596-6000 \n\nDay High: Day Low: Volume: \n\non \n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    },
    {
      "section_name": "Email Alerts",
      "links": [
        {
          "title": "Email Alerts",
          "url": "http://investors.vcel.com/email-alerts",
          "content": "[Skip to main content](#ndq-content)\n\nVericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.\n\n[Accept and Close](#)\n\n[Privacy Policy](https://vcel.com/privacy-policy/)\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[](https://twitter.com/VericelCorp) [](https://www.facebook.com/VericelCorp) [](https://www.linkedin.com/company/vericel-corporation)\n\n[In the News](https://vcel.com/#news)\n\n# Investor Relations\n\nAdvanced therapies for the sports medicine and severe burn care markets\n\n[Investor Relations](/)\n\n#  Email Alerts \n\n#  Email Alerts \n\nYou may automatically receive Vericel Corporation financial information by email. Please enter your preferences for email notifications below.\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote By Email  \nAll SEC Filings  \nCorporate Press Releases  \nFinancial Press Releases  \n  \nEmail\n\nLeave this field blank\n\n[Unsubscribe from Investor Relations email alerts.](/unsubscribe-0)\n\nOur email alerts provide automated opt-out methods as well as complete contact information.\n\nDay High: Day Low: Volume: \n\non \n\nData Provided by Refinitiv. Minimum 15 minutes delayed.\n\n### \n\nCompany Presentation \n\n[![Investor Presentation Title Slide](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2019/05/21/13-48-04/Presentation%20Title%20Slide.jpg?itok=b1iba_Oo) ](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf)\n\n[Company Presentation](/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcf \"Vericel Company Presentation - November 2024.pdf\") 2.6 MB\n"
        }
      ]
    }
  ]
}